Kurzübersicht für Parkin Antikörper (N-Term) (ABIN390387)
Target
Parkin (PARK)
Reaktivität
Drosophila melanogaster
Wirt
Kaninchen
Klonalität
Polyklonal
Konjugat
Dieser Parkin Antikörper ist unkonjugiert
Applikation
Western Blotting (WB)
Klon
RB8213
Bindungsspezifität
AA 82-111, N-Term
Aufreinigung
This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
Immunogen
This Drosophila Parkin antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 82-111 amino acids from the N-terminal region of human Drosophila Parkin.
PARK
Reaktivität: Drosophila melanogaster
WB, EIA
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
WB: 1:1000
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Buffer
Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.
Haltbarkeit
6 months
Target
Parkin (PARK)
Andere Bezeichnung
Drosophila Parkin
Hintergrund
Parkin is thought to play a role in the ubiquitin/proteasome pathway for protein degradation. The amino terminus bears sequence homology to ubiquitin while functionally it acts as a RING-type ubiquitin protein ligase (E3) that coordinates the transfer of ubiquitin to substrate proteins, thus targeting them for degradation by the proteasome. Mutations in the human version of the protein are known to cause autosomal recessive juvenile parkinsonism.